Skip to main content
Fig. 5 | Journal of Inflammation

Fig. 5

From: A novel sphingosylphosphorylcholine and sphingosine-1-phosphate receptor 1 antagonist, KRO-105714, for alleviating atopic dermatitis

Fig. 5

Effects of KRO-105714 treatment on itch-scratch response (ISR) and DNCB-induced atopic dermatitis in animal models. a itch-scratch response (ISR) of evaluation of scratching behavior mouse model. To measure itch-related behavior induced by SPC, KRO-105714 was administered to ICR mice (8 weeks, male, n = 5 per group) via oral administration of 1 and 10 mg/kg KRO-105714 with the SPC application (100 nM/site), bouts of scratching were counted for 30 min. Data are shown as mean ± standard deviation (SD). *P < 0.05, and ** P < 0.01 versus mice with vehicle (n = 5) (ANOVA multiple comparison). b Images of skin lesions from the groups of mice were taken on the last day of the experiment (a; Non-treated, b; 0.2% DNCB, c; 0.2% DNCB/1% KRO-105714, d; 0.2% DNCB/1% hydrocortisone). Representative images from five different mice per group are shown

Back to article page